Hello, Pills!

September 7, 2020

With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral

More news on Isturisa for Cushing’s

June 10, 2020

In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult